Skip to main content
Top
Published in: International Journal of Clinical Oncology 4/2011

01-08-2011 | Case Report

Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura

Authors: Kimio Wakana, Toshiharu Yasugi, Yurie Nako, Tomomi Nei, Yoshikazu Ozaki, Katsumi Mizutani

Published in: International Journal of Clinical Oncology | Issue 4/2011

Login to get access

Abstract

Ovarian clear cell adenocarcinoma (OCCA) is known to have a worse prognosis than ovarian serous adenocarcinoma due to its poor response to conventional platinum-based chemotherapy. Idiopathic thrombocytopenic purpura (ITP), which usually reveals severe thrombocytopenia, is a common autoimmune disorder. However, to date very few cases of ovarian cancer associated with ITP have been reported in the literature. We report a case of a 57-year-old woman who developed OCCA 14 years after the diagnosis of ITP. The patient presented with abdominal distention and mild tenderness. We performed the operation with high-dose immunoglobulin therapy preoperatively, and diagnosed OCCA. Postoperatively, six cycles of cytotoxic chemotherapy with irinotecan hydrochloride plus cisplatin were performed every 4–5 weeks without thrombocytopenia. We conclude that combination chemotherapy with irinotecan hydrochloride plus cisplatin is useful for a case of OCCA associated with ITP.
Literature
1.
go back to reference Sugiyama T, Yakushiji M, Kamura T, Japan CPT-11 Study Group et al (2002) Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology 63:16–22PubMedCrossRef Sugiyama T, Yakushiji M, Kamura T, Japan CPT-11 Study Group et al (2002) Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology 63:16–22PubMedCrossRef
2.
go back to reference Peffault de Latour R, Des Guetz G, Laurence V et al (2004) Breast cancer associated with idiopathic thrombocytopenic purpura: a single center series of 10 cases. Am J Clin Oncol 27:333–336PubMedCrossRef Peffault de Latour R, Des Guetz G, Laurence V et al (2004) Breast cancer associated with idiopathic thrombocytopenic purpura: a single center series of 10 cases. Am J Clin Oncol 27:333–336PubMedCrossRef
3.
go back to reference Chehal A, Taher A, Seoud M et al (2003) Idiopathic thrombocytopenic purpura and ovarian cancer. Eur J Gynaecol Oncol 24:539–540PubMed Chehal A, Taher A, Seoud M et al (2003) Idiopathic thrombocytopenic purpura and ovarian cancer. Eur J Gynaecol Oncol 24:539–540PubMed
4.
go back to reference Tarraza HM, Carroll R, De Cain M et al (1991) Recurrent ovarian carcinoma: presentation as idiopathic thrombocytopenic purpura and a splenic mass. Eur J Gynaecol Oncol 12:439–443PubMed Tarraza HM, Carroll R, De Cain M et al (1991) Recurrent ovarian carcinoma: presentation as idiopathic thrombocytopenic purpura and a splenic mass. Eur J Gynaecol Oncol 12:439–443PubMed
5.
go back to reference George JN, Woolf SH, Raskob GE et al (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3–40PubMed George JN, Woolf SH, Raskob GE et al (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3–40PubMed
6.
go back to reference Cheng Y, Wong RS, Soo YO et al (2003) Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 349:831–836PubMedCrossRef Cheng Y, Wong RS, Soo YO et al (2003) Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 349:831–836PubMedCrossRef
7.
go back to reference Ozols RF, Bundy BN, Greer BE, Gynecologic Oncology Group et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194–3200PubMedCrossRef Ozols RF, Bundy BN, Greer BE, Gynecologic Oncology Group et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194–3200PubMedCrossRef
8.
go back to reference Takakura S, Takano M, Takahashi F, Japanese Gynecologic Oncology Group et al (2010) Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer 20:240–247PubMedCrossRef Takakura S, Takano M, Takahashi F, Japanese Gynecologic Oncology Group et al (2010) Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer 20:240–247PubMedCrossRef
Metadata
Title
Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura
Authors
Kimio Wakana
Toshiharu Yasugi
Yurie Nako
Tomomi Nei
Yoshikazu Ozaki
Katsumi Mizutani
Publication date
01-08-2011
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-010-0149-3

Other articles of this Issue 4/2011

International Journal of Clinical Oncology 4/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine